Hologic (HOLX) : Money flow in the Hologic (HOLX) stock was negative (2.01 million) on Thursday, which shows that the investors used the strength in the stock price to reduce their holdings. The total traded value on upticks was $7.76 million, compared to $9.76 million on downticks. The total uptick to downtick ratio was 0.79, indicating the underlying weakness in the stock. Even in block trades, money flow was negative ($2.1 million), indicating selling on the strength. The transaction value during uptick in block trades was $0.37 million. Downtick transaction value in block trades amounted to $2.47 million, indicating persistent selling. The uptick to downtick ratio was 0.15. Hologic (HOLX) traded $0.71 higher at $35.41 gaining 2.05% over the previous days close.
Hologic (HOLX) : The highest level Hologic (HOLX) is projected to reach is $46 for the short term and the lowest estimate is at $38. The consolidated price target from 12 rating analysts who initiate coverage on the stock is $42.25 and the possibility the share price can swing is $2.56. The stock has recorded a 20-day Moving Average of 4.19% and the 50-Day Moving Average is 3.98%.
Hologic (NASDAQ:HOLX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $34.70 and $34.61 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.79. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.50, notching a gain of 2.31% for the day. The total traded volume was 3,322,753 . The stock had closed at $34.70 on the previous day.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.